A new PROTAC platform is drawing renewed attention to the broader protein-degradation pipeline as Arvinas highlighted lessons from clinical-stage work. In an interview format, the company’s CEO Randy Teel discussed what comes next for degraders beyond the first wave, emphasizing translational considerations around targeting, dosing, and whether next-generation modalities can expand addressable protein space.